Surface activity of a synthetic lung surfactant containing a phospholipase-resistant phosphonolipid analog of dipalmitoyl phosphatidylcholine.

@article{Wang2003SurfaceAO,
  title={Surface activity of a synthetic lung surfactant containing a phospholipase-resistant phosphonolipid analog of dipalmitoyl phosphatidylcholine.},
  author={Z. Wang and Adrian L. Schwan and Luke L. Lairson and James S. O’Donnell and G F Byrne and Adam Foye and Bruce A. Holm and Robert H. Notter},
  journal={American journal of physiology. Lung cellular and molecular physiology},
  year={2003},
  volume={285 3},
  pages={
          L550-9
        }
}
  • Z. Wang, A. Schwan, +5 authors R. Notter
  • Published 1 September 2003
  • Biology
  • American journal of physiology. Lung cellular and molecular physiology
Surface activity and sensitivity to inhibition from phospholipase A2 (PLA2), lysophosphatidylcholine (LPC), and serum albumin were studied for a synthetic C16:0 diether phosphonolipid (DEPN-8) combined with 1.5% by weight of mixed hydrophobic surfactant proteins (SP)-B/C purified from calf lung surfactant extract (CLSE). Pure DEPN-8 had better adsorption and film respreading than the major lung surfactant phospholipid dipalmitoyl phosphatidylcholine and reached minimum surface tensions <1 mN/m… 
View on PubMed
ajplung.physiology.org
30 Citations
Highly Influential Citations
2
Background Citations
8
Methods Citations
4
Results Citations
2

Figures and Tables from this paper

30 Citations

Citation Type

Citation Type

Dynamic Surface Activity of a Fully Synthetic Phospholipase-Resistant Lipid/Peptide Lung Surfactant
TLDR
Results show that DEPN-8 and 1.5% Mini-B form an interactive binary molecular mixture with very high surface activity and the ability to resist degradation by phospholipases in inflammatory lung injury, which are promising for the development of related fully-synthetic lipid/peptide exogenous surfactants for treating diseases of surfactant deficiency or dysfunction.
Surface properties of sulfur- and ether-linked phosphonolipids with and without purified hydrophobic lung surfactant proteins.
Activity and inhibition resistance of a phospholipase-resistant synthetic surfactant in rat lungs.
TLDR
The results support the potential of developing highly active and inhibition-resistant synthetic exogenous surfactants containing DEPN-8 + apoprotein/peptide constituents for use in treating direct pulmonary forms of clinical acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS).
Synthetic lung surfactants containing SP-B and SP-C peptides plus novel phospholipase-resistant lipids or glycerophospholipids
TLDR
The findings support the potential of dual-peptide synthetic lipid/ peptide surfactants containing S-MB DATK + SP-Css ion-lock 1 for treating diseases of surfactant deficiency or dysfunction and may have particular applications in treating direct forms of ARDS.
An albumin-associated PLA2-like activity inactivates surfactant phosphatidylcholine secreted from fetal type II pneumocytes.
  • J. E. Damas, M. Cake
  • Biology
    American journal of physiology. Lung cellular and molecular physiology
  • 2011
TLDR
This study has shown that, when cultured type II pneumocytes are exposed to lipoprotein-free serum (LFS), the level of lyso-phosphatidylcholine (lyso-PC) in the secreted surfactant phospholipids is markedly elevated with a concomitant decline in the level in the media.
Inhibition of surfactant activity by Pneumocystis carinii organisms and components in vitro.
TLDR
Results indicate that in addition to surfactant dysfunction induced by inflammatory lung injury and edema-derived inhibitors in Pc pneumonia, disrupted Pc organisms in the alveolar lumen also have the potential to directly inhibit endogenous and exogenous lung surfactants in affected patients.
Composition, Structure and Biophysical Functions of Pulmonary Surfactants: Their Deficiency and Strategy for Remedy
Pulmonary surfactant (PS) is a complex mixture of lipids and proteins that forms a monomolecular film at the lung-air interface. It serves dual purposes: (i) lowers the surface tension; and (ii)…
Molecular interactions of cord factor with dipalmitoylphosphatidylcholine monolayers: implications for lung surfactant dysfunction in pulmonary tuberculosis.
Inactivation of pulmonary surfactant due to serum-inhibited adsorption and reversal by hydrophilic polymers: experimental.
TLDR
Observation that addition of either hyaluronan or polyethylene glycol to subphases containing serum reversed inhibition by restoring the rate of surfactant adsorption to that of the clean interface, thereby allowing surfactants to overcome the serum-induced barrier to adsorb reversibly.
Overcoming rapid inactivation of lung surfactant: analogies between competitive adsorption and colloid stability.
...
1
2
3
...

References

SHOWING 1-10 OF 67 REFERENCES
Chemical synthesis and surface activity of lung surfactant phospholipid analogs. II. Racemic N-substituted diether phospholipids
Chemical synthesis and surface activity of lung surfactant phospholipid analogs. II. Racemic N-substituted diether phosphonolipids.
TLDR
Findings suggest that selected analog compounds, synthesized with relatively small structural modifications from biologic glycerophospholipids, may have eventual applications as components of synthetic exogenous lung surfactants.
Additivity of protein and nonprotein inhibitors of lung surfactant activity.
  • Z. Wang, R. Notter
  • Biology
    American journal of respiratory and critical care medicine
  • 1998
TLDR
Results indicate that surfactant dysfunction in acute respiratory distress syndrome (ARDS) could be increased in severity by interactions between some inhibitory substances, but that supplementation with exogenous CLSE would be effective in reversing inactivation by the mixtures of blood proteins, membrane lipids, and fatty acids studied.
In vivo function of surfactants containing phosphatidylcholine analogs.
TLDR
DEPC and DEPnC were as effective as DPPC as lipid components of synthetic surfactants for certain lung injuries and improved in vivo function to levels comparable to LES.
A diether phosphonolipid surfactant analog, DEPN-8, is resistant to phospholipase-C cleavage.
TLDR
The results suggest that (R)(S)-DEPN-8 and structurally related analogs may be useful as components of exogenous replacement surfactant formulations for the treatment of ARDS-related lung injuries.
A competitive inhibitor of phospholipase A2 decreases surfactant phosphatidylcholine degradation by the rat lung.
TLDR
A significant role for acidic Ca(2+)-independent PLA2 in the degradation of internalized alveolar PC is demonstrated, but further indicate that this enzyme accounts for a minor fraction of total lung PC metabolism.
Multiple Mechanisms of Lung Surfactant Inhibition
TLDR
The ability of LPC or other cell membrane lipids to penetrate interfacial films and raise γmin even at high surfactant concentration may increase their inhibitory actions during acute lung injury.
Bilayer characteristics of a diether phosphonolipid analog of the major lung surfactant glycerophospholipid dipalmitoyl phosphatidylcholine.
Dynamic Interfacial Properties of Surface-excess Films of Phospholipids and Phosphonolipid Analogs
Abstract Dynamic surface pressure-area (π-A) isotherms were measured for dipalmitoyl phosphatidylcholine (DPPC), dipalmitoyl phosphatidylethanolamine (DPPE), and 13 chain-equivalent synthetic…
Chemical synthesis and surface properties of an analog of the pulmonary surfactant dipalmitoyl phosphatidylcholine.
...
1
2
3
4
5
...